Search

Displaying results 1021 - 1030 of 8468 in total
  1. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285] … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].

  2. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  3. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    [A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.

  4. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

  5. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. … It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

  6. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

    Mixtures: Mencevax Ac Pws 50mcg/vial, Mencevax Ac Pws 500mcg/vial
  7. Drug

    Guaiacol

    go.drugbank.com/drugs/DB11359
    Approved

    Guaiacol is also present in wood smoke, as a product of pyrolysis of lignin. Guaiacol has been found in the urine of patients with neuroblastoma and pheochromocytoma. … Guaiacol is an agent thought to have disinfectant properties and used as an expectorant. Guaiacol is a phenolic natural product first isolated from Guaiac resin and the oxidation of lignin.

  8. Target

    Plasminogen activator inhibitor 1

    go.drugbank.com/bio_entities/BE0000240
    TargetHumans

    Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-re...

    Synonyms: PAI, PAI-1
  9. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [L12624] It is additionally approved in Canada under the same name (Imfinzi) for similar indications, as well as the treatment of patients with locally advanced or metastatic urothelial carcinoma. … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage

  10. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    response to standardized antituberculosis treatments as [DB00951] and [DB01045]. … Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).